Julia G. Butchko Sells 1,527 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

Immunovant, Inc. (NASDAQ:IMVT) insider Julia G. Butchko sold 1,527 shares of Immunovant stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $28.06, for a total value of $42,847.62. Following the transaction, the insider now owns 446,853 shares of the company’s stock, valued at $12,538,695.18. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Immunovant Stock Performance

Immunovant stock opened at $30.57 on Friday. Immunovant, Inc. has a 52 week low of $18.82 and a 52 week high of $45.58. The stock has a market capitalization of $4.47 billion, a P/E ratio of -16.09 and a beta of 0.67. The stock has a fifty day moving average of $27.85 and a 200-day moving average of $32.50.

Immunovant (NASDAQ:IMVT) last issued its earnings results on Wednesday, May 29th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). During the same period last year, the business earned ($0.46) earnings per share. On average, research analysts forecast that Immunovant, Inc. will post -2.11 earnings per share for the current year.

Hedge Funds Weigh In On Immunovant

A number of institutional investors and hedge funds have recently bought and sold shares of IMVT. Point72 Asset Management L.P. acquired a new position in Immunovant in the 4th quarter worth about $112,356,000. Octagon Capital Advisors LP increased its holdings in Immunovant by 127.3% in the 4th quarter. Octagon Capital Advisors LP now owns 273,289 shares of the company’s stock worth $11,514,000 after purchasing an additional 1,273,289 shares in the last quarter. Vanguard Group Inc. increased its holdings in Immunovant by 14.0% in the 3rd quarter. Vanguard Group Inc. now owns 6,233,146 shares of the company’s stock worth $239,290,000 after purchasing an additional 764,530 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Immunovant in the 4th quarter valued at about $22,712,000. Finally, First Turn Management LLC bought a new stake in shares of Immunovant in the 4th quarter valued at about $21,608,000. Institutional investors and hedge funds own 47.08% of the company’s stock.

Analyst Upgrades and Downgrades

IMVT has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunovant in a research note on Tuesday, June 18th. Truist Financial reiterated a “buy” rating and set a $48.00 target price on shares of Immunovant in a research note on Monday, March 25th. Oppenheimer reduced their target price on Immunovant from $50.00 to $46.00 and set an “outperform” rating for the company in a research note on Monday, June 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $51.00 target price on shares of Immunovant in a research note on Thursday, May 30th. Sixteen equities research analysts have rated the stock with a buy rating, According to MarketBeat, Immunovant has a consensus rating of “Buy” and a consensus target price of $48.75.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.